Varicella-Zoster immunoglobulins


Concise Prescribing Info
Indications/Uses
Passive immunisation against varicella infections.
Dosage/Direction for Use
Adult : IM Dosing is based on patient's wt. ≤10 kg: 125 u; 10.1-20 kg: 250 u; 20.1-30 kg: 375 u; 30.1-40 kg: 500 u; >40 kg: 625 u. To be given as a single deep inj; if the vol to be injected is >5 mL, dose should be divided and administered at different sites. May repeat dose at 3-wk intervals if patient is re-exposed or continuously exposed to varicella until the risk of exposure is no longer present. Dose should preferably be given w/in 48 hr but no later than 96 hr after exposure.
Dosage Details
Intramuscular
Passive immunisation against varicella infections
Adult: Dosing is based on patient's weight. ≤10 kg: 125 units; 10.1-20 kg: 250 units; 20.1-30 kg: 375 units; 30.1-40 kg: 500 units; >40 kg: 625 units. To be given as a single deep IM inj; if the volume to be injected is >5 ml, dose should be divided and administered at different sites. May repeat dose at 3-wk intervals if patient is re-exposed or continuously exposed to varicella until the risk of exposure is no longer present. Dose should preferably be given within 48 hr after exposure but no later than 96 hr after exposure.
Child: Dosing is based on patient's weight. ≤10 kg: 125 units; 10.1-20 kg: 250 units; 20.1-30 kg: 375 units; 30.1-40 kg: 500 units; >40 kg: 625 units. To be given as a single deep IM inj; if the volume to be injected is >5 ml, dose should be divided and administered at different sites. May repeat dose at 3-wk intervals if patient is re-exposed or continuously exposed to varicella until the risk of exposure is no longer present. Dose should preferably be given within 48 hr after exposure but no later than 96 hr after exposur
Contraindications
History of hypersensitivity to immune globulins. IM admin should not be used in patients with severe thrombocytopenia or coagulation disorders.
Special Precautions
Caution when used in patients with a specific IgA deficiency due to possible presence of antibodies to IgA. Risk of transmitting infectious agents thus vaccination should be considered where appropriate. Caution when used in pregnant and lactating women.
Adverse Reactions
Inj site reactions e.g. local erythema, redness and pain. GI symptoms, malaise, headache, rash and respiratory symptoms. Chest pain, dyspnoea, tremor, dizziness, glossitis, buccal ulceration, facial oedema, arthralgia.
IM/Parenteral: C
Drug Interactions
Concurrent use may interfere with the immune response to certain live vaccines.
Action
Description: Varicella-zoster immunoglobulins are used for passive immunisation against varicella. It is recommended for use in susceptible persons who are at high risk of developing varicella-associated complications after exposure to varicella or herpes zoster (shingles).
Storage
Store at 2-8°C.
Disclaimer: This information is independently developed by MIMS based on Varicella-Zoster immunoglobulins from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in